#ITI#Protective efficacy of H7 subtype avian influenza DNA vaccine#FTI#
#IRE#Highly pathogenic avian influenza viruses (HPAIV) have historically caused disastrous damage to the poultry industry, and recently they have shown their zoonotic potential by causing human infections and deaths. Control and prevention of HPAIV are therefore important issues for both veterinary and human public health. In this study, we constructed a plasmid, pCAGGoptiH7, encoding a codon-optimized HA gene of the H7N1 avian influenza virus A/FPV/Rostock/34 (RK/34). To evaluate the vaccine efficacy of pCAGGoptiH7, groups of specific-pathogen-free (SPF) chickens were intramuscularly inoculated with one or two doses of 100 μg, 50 μg, or 10 μg of the plasmid in 3-wk intervals. Four weeks after the single vaccination or 2 wk after the second dose, all chickens were challenged with 100CLD50 (chicken lethal dose) of highly pathogenic RK/34. After the single dose vaccination, only 90% of chickens were protected in all of the pCAGGoptiH7-immunized groups, although all of the chickens immunized generated detectable HI antibodies. After the second dose of vaccination, HI antibodies increased sharply, and chickens in the 100-μg and 50-μg pCAGGoptiH7-immunized groups were completely protected from virus challenge (no disease signs, no virus shedding, and no deaths). Low titers of virus shedding were detected in two out of ten chickens inoculated with two doses of 10-μg pCAGGoptiH7, although no disease or death was observed. These results provide a strong argument for the continued evaluation of this vaccine in field trials. © 2010 American Association of Avian Pathologists.#FRE#
#IPC#Avian influenza virus; DNA vaccine; H7 subtype#FPC#
#IRF#Cherbonnel M., Rousset J., Jestin V., Strategies to improve protection against low-pathogenicity H7 avian influenza virus infection using DNA vaccines, Avian Dis., 47, 3 SUPPL., pp. 1181-1186, (2003); 
Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., Kuiken T., Rimmelzwaan G.F., Schutten M., Van Doornum G.J., Koch G., Bosman A., Koopmans M., Osterhaus A.D., Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome, Proc. Natl. Acad. Sci. U. S. A., 101, 5, pp. 1356-1361, (2004); 
Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L., DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations, Proc. Natl. Acad. Sci. U. S. A., 90, 24, pp. 11478-11482, (1993); 
Hirst M., Astell C.R., Griffith M., Coughlin S.M., Moksa M., Zeng T., Smailus D.E., Holt R.A., Jones S., Marra M.A., Petric M., Krajden M., Lawrence D., Mak A., Chow R., Skowronski D.M., Tweed S.A., Goh S., Brunham R.C., Robinson J., Bowes V., Sojonky K., Byrne S.K., Li Y., Kobasa D., Booth T., Paetzel M., Novel avian influenza H7N3 strain outbreak, British Columbia, Emerg. Infect. Dis., 10, 12, pp. 2192-2195, (2004); 
Holm L., Codon usage and gene expression, Nucleic Acids Res., 14, 7, pp. 3075-3087, (1986); 
Jiang Y., Yu K., Zhang H., Zhang P., Li C., Tian G., Li Y., Wang X., Ge J., Bu Z., Chen H., Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector, Antiviral Res., 75, 3, pp. 234-241, (2007); 
Koopmans M., Wilbrink B., Conyn M., Natrop G., Van Der Nat H., Vennema H., Meijer A., Van Steenbergen J., Fouchier R., Osterhaus A., Bosman A., Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands, Lancet, 363, 9409, pp. 587-593, (2004); 
Larsen D.L., Olsen C.W., Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs, Am. J. Vet. Res., 63, 5, pp. 653-659, (2002); 
Le Gall-Recule G., Cherbonnel M., Pelotte N., Blanchard P., Morin Y., Jestin V., Importance of a prime-boost DNA/protein vaccination to protect chickens against low-pathogenic H7 avian influenza infection, Avian Dis., 51, 1 SUPPL., pp. 490-494, (2007); 
Li Y., Li C., Liu L., Wang H., Wang C., Tian G., Webster R.G., Yu K., Chen H., Characterization of an avian influenza virus of subtype H7N2 isolated from chickens in northern China, Virus Genes, 33, pp. 117-122, (2006); 
Maines T.R., Chen L.M., Matsuoka Y., Chen H., Rowe T., Ortin J., Falcon A., Nguyen T.H., Mai Le Q., Sedyaningsih E.R., Harun S., Tumpey T.M., Donis R.O., Cox N.J., Subbarao K., Katz J.M., Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model, Proc. Natl. Acad. Sci. U. S. A., 103, 32, pp. 12121-12126, (2006); 
Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza, Lancet, 357, 9272, pp. 1937-1943, (2001); 
Facts & Figures, Avian Influenza; 
Robinson H.L., Hunt L.A., Webster R.G., Protection against a lethal influenza virus challenge by immunization with a haemagglutinin expressing plasmid DNA, Vaccine, 11, 9, pp. 957-960, (1993); 
Sakabe S., Sakoda Y., Haraguchi Y., Isoda N., Soda K., Takakuwa H., Saijo K., Sawata A., Kume K., Hagiwara J., Tuchiya K., Lin Z., Sakamoto R., Imamura T., Sasaki T., Kokumai N., Kawaoka Y., Kida H., A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens, Vaccine, 26, 17, pp. 2127-2134, (2008); 
Sambrook J., Fritsh F.E.F., Maniatis T., Molecular Cloning-A Laboratory Manual, (1989); 
Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., Katz J.M., Confronting the avian influenza threat: Vaccine development for a potential pandemic, Lancet Infect. Dis., 4, 8, pp. 499-509, (2004); 
Suarez D.L., Schultz-Cherry S., The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in chickens using as avian influenza model, Avian Dis., 44, 4, pp. 861-868, (2000); 
Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., Matsuoka Y., Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics, Virology, 305, 1, pp. 192-200, (2003); 
Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M., Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine, N. Engl. J. Med., 354, 13, pp. 1343-1351, (2006); 
Tweed S.A., Skowronski D.M., David S.T., Larder A., Petric M., Lees W., Li Y., Katz J., Krajden M., Tellier R., Halpert C., Hirst M., Astell C., Lawrence D., Mak A., Human illness from avian influenza H7N3, British Columbia, Emerg. Infect. Dis., 10, 12, pp. 2196-2199, (2004)#FRF#
